Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer
Status:
Recruiting
Trial end date:
2021-09-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects of durvalumab and chemotherapy before surgery in
treating patients with variant histology bladder cancer. Immunotherapy with monoclonal
antibodies, such as durvalumab, may induce changes in the body's immune system and may
interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy,
such as methotrexate, vinblastine, doxorubicin, cisplatin, gemcitabine, and carboplatin, work
in different ways to stop the growth of tumor cells, either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. Giving durvalumab in addition to
standard chemotherapy may lead to better outcomes in patients with variant histology bladder
cancer.